Strongbridge Biopharma (SBBP) Downgraded by TheStreet

TheStreet cut shares of Strongbridge Biopharma (NASDAQ:SBBP) from a c- rating to a d+ rating in a report issued on Wednesday, TheStreetRatingsTable reports.

Several other research analysts have also issued reports on SBBP. ValuEngine lowered shares of Strongbridge Biopharma from a buy rating to a hold rating in a research note on Monday, February 4th. Oppenheimer set a $15.00 price target on shares of Strongbridge Biopharma and gave the stock a buy rating in a research note on Tuesday, February 26th. Cantor Fitzgerald set a $12.00 price target on shares of Strongbridge Biopharma and gave the stock a buy rating in a research note on Tuesday, February 26th. Zacks Investment Research upgraded shares of Strongbridge Biopharma from a hold rating to a buy rating and set a $5.75 price target for the company in a research note on Friday, March 1st. Finally, BidaskClub upgraded shares of Strongbridge Biopharma from a strong sell rating to a sell rating in a research note on Saturday, March 2nd. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and six have assigned a buy rating to the stock. Strongbridge Biopharma has an average rating of Hold and an average target price of $13.14.

Shares of Strongbridge Biopharma stock opened at $3.03 on Wednesday. The stock has a market capitalization of $164.14 million, a P/E ratio of 9.77 and a beta of 0.17. Strongbridge Biopharma has a 1 year low of $3.00 and a 1 year high of $7.82.

Strongbridge Biopharma (NASDAQ:SBBP) last issued its quarterly earnings results on Wednesday, May 1st. The biotechnology company reported ($0.34) earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.43) by $0.09. The company had revenue of $4.34 million during the quarter, compared to analyst estimates of $4.69 million. Strongbridge Biopharma had a net margin of 227.79% and a return on equity of 79.31%. On average, analysts anticipate that Strongbridge Biopharma will post -1.36 earnings per share for the current year.

A number of large investors have recently added to or reduced their stakes in the business. BlueCrest Capital Management Ltd increased its stake in Strongbridge Biopharma by 41.5% during the 1st quarter. BlueCrest Capital Management Ltd now owns 40,240 shares of the biotechnology company’s stock valued at $200,000 after purchasing an additional 11,805 shares in the last quarter. Morgan Stanley increased its stake in Strongbridge Biopharma by 528.2% during the 1st quarter. Morgan Stanley now owns 71,264 shares of the biotechnology company’s stock valued at $355,000 after purchasing an additional 59,920 shares in the last quarter. Jefferies Group LLC bought a new stake in Strongbridge Biopharma during the 1st quarter valued at about $374,000. ExodusPoint Capital Management LP bought a new stake in Strongbridge Biopharma during the 1st quarter valued at about $167,000. Finally, Renaissance Technologies LLC bought a new stake in Strongbridge Biopharma during the 1st quarter valued at about $269,000. Institutional investors and hedge funds own 49.11% of the company’s stock.

Strongbridge Biopharma Company Profile

Strongbridge Biopharma plc, a commercial-stage biopharmaceutical company, focuses on the development and commercialization of therapies for rare diseases with unmet needs. The company's commercial products include Keveyis, an oral carbonic anhydrase inhibitor for treating hyperkalemic, hypokalemic, and related variants of primary periodic paralysis in the United States; and Macrilen, an oral growth hormone secretagogue receptor agonist for use in the diagnosis of patients with adult growth hormone deficiency.

Recommended Story: Why is the conference call important?

Analyst Recommendations for Strongbridge Biopharma (NASDAQ:SBBP)

Receive News & Ratings for Strongbridge Biopharma Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Strongbridge Biopharma and related companies with MarketBeat.com's FREE daily email newsletter.